Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “GASTROINTESTINAL DISEASE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources
PubMed2001

[Somatic vascular and psycho-emotional disorders in some gastrointestinal diseases and the correction with physical factors].

Vegetovascular disorders are obligatory and even leading clinical manifestations of chronic gastrointestinal diseases. Physiotherapy in combination with psychotherapy produce a normalizing effect on functional-morphological condition of the gastrointestinal organs, correct alterations in the neuropsychic sphere and autonomic nervous system.

Cerebrovascular Disorders↗
PubMed1991

The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis.

The gastrointestinal tract is a rich source of mast cells with an enormous surface area that permits a high degree of interaction between the mast cell and intestinal luminal contents. The active metabolic products of the mast cell influence gastrointestinal secretion, absorption, and motility through paracrine effects of local mast cell degranulation and also cause systemic effects through the release of cellular products into the blood stream. Systemic mastocytosis influences physiologic function through the systemic effects of mast cell products released from focal (e.g., bone marrow) or wide spread increases in mast cell number. Local gastrointestinal proliferation of mast cells in response to recognized (e.g., gluten in celiac sprue) or obscure stimuli can alter gastrointestinal function and induce systemic symptoms. Celiac sprue, inflammatory bowel disease, and non-ulcer dyspepsia are three examples of gastrointestinal diseases in which mast cells can be implicated in the pathophysiology of the symptoms.

Celiac Disease↗
PubMed2001

[Relation between infection of CagA-positive Helicobacter pylori and upper gastrointestinal diseases].

OBJECTIVE: To study the relation between infection of Helicobacter pylori strains expressing CagA and upper gastrointestinal diseases, and to assess the change of anti-CagA IgG antibody levels after eradication of H. pylori. METHODS: Gastric biopsy was conducted among eight hundred and eight patients who received endoscopy to determine the pathological changes of mucosa and infectious status of H. pylori. The presence of serum anti-CagA IgG was detected in each H. pylori-positive patient by ELISA. Eradication therapy by PPI was conducted to the H. pylori-positive individuals. The anti-CagA IgG levels were reexamined among 60 patients whose H. pylori infection failed to be eradicated and 120 patients whose H. pylori infection was successfully eradicated after 3 months and 6 months. RESULTS: The serum anti-CagA IgG-positive rates were 55.4%, 70.5%, 83.2%, 90.8% and 89.7% in H. pylori-positive patients with chronic superficial gastritis (CSG), chronic atrophic gastritis (CAG), gastric ulcer (GU), duodenal ulcer (DU), and gastric cancer (GC) respectively. The serum anti-CagA IgG-positive rates among the latter 4 groups were significantly higher than that in CSG group, and the serum anti-CagA IgG-positive rates among the latter 3 groups were significantly higher than that in CAG group. The serum anti-CagA IgG-positive rate among patients with CAG was significantly higher than that among patients with CSG (P < 0.05). The CagA-positive rates in the groups of intestinal metaplasia (IM), atypical hyperplasia and GC were significantly higher than those in the groups of CSG and CAG (P < 0.05). By the end of 3 and 6 months after the eradication therapy, the antibody level had decreased from a mean value of (69 +/- 38) U/ml to (47 +/- 30) U/ml and (32 +/- 15) U/ml among 120 patients with successful eradication and the serum antibody reverted to negative only in 23 cases from them. There was no significant change in serum anti-CagA IgG level among 60 patients without successful eradication. CONCLUSION: Infection with CagA-positive H. pylori strains is associated with an increased risk of developing more severe gastroduodenal diseases and more severe gastric mucosa lesions. Despite an overall significant decrease of anti-CagA IgG level in sera after H. pylori eradication, this serological method cannot be used to monitor individual treatment effect because the anti-CagA IgG level decreases slowly.

Adult↗
PubMed1983

Simplified intravenous nutrition using Intralipid-based mixtures in patients with serious gastrointestinal disease.

An Intralipid-based intravenous feeding mixture has been given to 20 patients with serious gastrointestinal disease who required parenteral nutritional support (mean duration 13.75 days). In half of the patients, only peripheral veins were used for infusion (mean duration 12 days), the infusion site being changed every 24-48 hr. Positive nitrogen balance was maintained in all but one individual and other parameters of nutrition improved. No serious complications due to intravenous feeding were encountered, although some patients did develop abnormal liver function tests and mild phlebitis at the peripheral vein infusion site. No abnormalities of pulmonary gas exchange attributable to the infusion were noted. We conclude that this mixture is safe, relatively simple to use and effective. Consequently, it may be especially appropriate for patients in general medical and surgical wards as well as those in specialist units.

Adult↗
PubMed1996

[75-Se-labeled bile acid analog absorption in various gastrointestinal diseases using a whole body counter].

AIM: It is possible to detect disturbances of bile acid absorption using a whole body counter after administration of Se-75 labelled bile acid analogues. We scrutinized the benefit of a modification of the test method. METHODS: We investigated 77 patients with different forms of a gastrointestinal disease. After application of Se 75 homotaurocholic acid we measured patient-activity up to 7 days later including whole-body profile scans in the first 6 h. RESULTS: The fractional retention after 7 days was between 20 and 67%. In cases of impaired absorption it was below 12%. Patients with liver diseases and after cholecystectomy (without bile acid resorption disturbance) showed normal values. Patients with Crohn's disease of the ileum or with intestinal ileac by-pass or with colestyramine treatment or with disturbance of vitamin B12-absorption or with cystic fibrosis showed a disturbance of bile acid absorption. The normal whole-body half-life was more than 2.8 days. The 24 and 72 h values were 62 and 31% in cases with normal absorption. Smaller values are signs of bile acid malabsorption. Impulse rates measured with the whole body counter are of an order of magnitude that allows to reduce the usually administered dose of 37 kBq to 9.25 kBq. CONCLUSION: This is an efficient method to detect disturbances of bile acid absorption. The usually administered activity of 37 kBq can be reduced to 9.25 kBq.

Adult↗
PubMed1990

[The role of emotional stress in pathogenesis of gastrointestinal diseases and the importance of psychopharmacologic combinations in their treatment].

In view of the importance of the emotional stress in some gastrointestinal diseases pathogenesis among which anxiety and/or depression appear to play an appreciable role, the Authors have analysed a number of sensitive colon and duodenal ulcers whose psychopharmacologic treatment has resulted crucial in the resolution of these diseases.

Animals↗
PubMed1991

Adherent gram-positive cocci on the intestinal villi of two dogs with gastrointestinal disease.

Two dogs were examined for clinical signs of chronic gastrointestinal disease. Duodenal mucosal biopsy specimens, obtained endoscopically, revealed histologic lesions of adherent gram-positive cocci on the villus epithelium of both dogs. The positive gram stain and morphologic features of the adherent cocci were suggestive of Streptococcus organisms. Indirect tests for intestinal bacterial overgrowth were not diagnostic, suggesting that the adherent cocci were a primary lesion. Rapid clinical response following dietary manipulation and the initiation of medical management was observed in both dogs. The dogs of this report draw similarities to Streptococcus durans infection previously reported in pigs, foals, and a single pup. The pathogenesis of enteric disease associated with adherent gram-positive cocci in dogs remains ill-defined.

Animals↗
PubMed1977

[Characteristics of bacteria of the genus Citrobacter, isolated from healthy children and children with different acute gastrointestinal diseases].

The authors examined 250 children suffering from various acute gastrointestinal diseases, and 100 healthy children. Positive cultures of bacteria belonging to the Citrobacter genus were obtained in 38% of the patients and in 20% of the healthy persons. There were revealed no cultural or biochemical differences between the strains isolated from the sick and healthy individuals. There were revealed no cultural or biochemical differences between the strains isolated from the sich and healthy persons. A total of 189 strains were identified serologically. Serological types 01, 03, 04, 08, 021, 022, the ones most frequently encountered in sick children, were absent or rarely found in the healthy. Sensitivity of the majority of the strians to the main antibiotics used in medical practice was weak; the strain isolated from the sick and healthy children failed to differ by the antibiotic sensitivity.

Acute Disease↗
PubMed1995

Aspects of quality of life in gastrointestinal disease: some methodological issues.

Quality of Life assessments have many applications in clinical trials. In the evaluation of gastrointestinal disease for example. Quality of Life outcomes provide a useful tool for assessing treatment response. There are a number of standard measures currently available that may be utilized to determine Quality of Life. In clinical trials the use of questionnaires allows the clinician to assess the impact of disease and its subsequent treatment upon the patient's daily life. In order to facilitate comparison of data between studies, it is important that the measures selected are well validated. Patients with gastrointestinal problems do not only experience symptoms. The symptoms have an adverse impact on well-being and ability to enjoy day-to-day activities. It is important to provide appropriate treatment for the large and heterogeneous population with gastrointestinal complaints who have a poor Quality of Life.

Female↗
PubMed2005

[Vitamin metabolism and status in patients with gastrointestinal diseases].

Principle differences in vitamin C, B2, B6, A, E and carotenoids sufficiency of healthy suffering from gastrointestinal diseases (gastric and duodenal ulcer, chronic gastritis, dyskinesia bile tracts) ulc adults and children has not been determined by means of the statistic analysis including such parameters as median, mode, insufficiency frequency, curves of vitamin blood plasma concentration distribution. Polyhypovitaminosis frequency among patients is a result of low vitamin content in reduced diets but not reflect vitamin metabolism alteration.

Adult↗
PubMed1979

Anesthetic considerations in surgery for gastrointestinal disease.

We have attempted to present a brief overview of current considerations in anesthesia for surgery of gastrointestinal disease as practiced at our institution. Many considerations remain unexplored owing to limitations of space. We have deliberately concentrated upon antecedent and concurrent therapy encountered in the treatment of the surgical patient. The potent drugs introduced in the past decade have produced infinite potential for drug interactions--some serious, some not so serious, and some which are desirable. We hope we have generated further reader interest in this mushrooming problem of modern medicine confronting the anesthesiologist and surgeon in the perioperative period.

Aged↗
PubMed2003

An update on aspects of viral gastrointestinal diseases of dogs and cats.

Viruses commonly cause gastrointestinal illnesses in dogs and cats that range in severity from mild diarrhoea to malignant neoplasia. Perpetual evolution of viruses is reflected in changing disease patterns, so that familiar viruses are sometimes discovered to cause new or unexpected diseases. For example, canine parvovirus (CPV) has regained the ability to infect felids and cause a panleucopenia-like illness. Feline panleucopenia virus (FPV) has been shown to cause fading in young kittens and has recently been implicated as a possible cause of feline idiopathic cardiomyopathy. Molecular scrutiny of viral diseases sometimes permits deeper understanding of pathogenesis and epizootiology. Feline gastrointestinal lymphomas have not, in the past, been strongly associated with retroviral infections, yet some of these tumours harbour retroviral proviruses. Feline leukaemia virus (FeLV) may play a role in lymphomagenesis, even in cats diagnosed as uninfected using conventional criteria. There is strong evidence that feline immunodeficiency virus (FIV) can also be oncogenic. The variant feline coronaviruses that cause invariably-fatal feline infectious peritonitis (FIP) arise by sporadic mutation of an ubiquitous and only mildly pathogenic feline enteric coronavirus (FECV); a finding that has substantial management implications for cat breeders and veterinarians. Conversely, canine enteric coronavirus (CECV) shows considerable genetic and antigenic diversity but causes only mild, self-limiting diarrhoea in puppies. Routine vaccination against this virus is not recommended. Although parvoviruses, coronaviruses and retroviruses are the most important known viral causes of canine and feline gastrointestinal disease, other viruses play a role. Feline and canine rotaviruses have combined with human rotaviruses to produce new, reassortant, zoonotic viruses. Some companion animal rotaviruses can infect humans directly. Undoubtedly, further viral causes of canine and feline gastrointestinal disease await discovery.

Journal Article↗
PubMed1996

Nutrition and gastrointestinal disease.

Nutrition and intestinal function are intimately interrelated. The chief purpose of the gut is to digest and absorb nutrients in order to maintain life. Consequently, chronic gastrointestinal (GI) disease commonly results in malnutrition and increased morbidity and mortality. For example, studies have shown that 50-70% of adult patients with Crohn's disease were weight-depleted and 75% of adolescents growth-retarded. On the other hand, chronic malnutrition impairs digestive and absorptive function because food and nutrients are not only the major trophic factors to the gut but also provide the building blocks for digestive enzymes and absorptive cells. For example, recent studies of ours have shown that a weight loss of greater than 30% accompanying a variety of diseases was associated with a reduction in pancreatic enzyme secretion of over 80%, villus atrophy and impaired carbohydrate and fat absorption. Finally, specific nutrients can induce disease, for example, gluten-sensitive enteropathy, whilst dietary factors such as fibre, resistant starch, short-chain fatty acids, glutamine and fish-oils may prevent gastrointestinal diseases such as diverticulitis, diversion colitis, ulcerative colitis, colonic adenomatosis and colonic carcinoma. The role of dietary antigens in the aetiology of Crohn's disease is controversial, but controlled studies have suggested that elemental diets may be as effective as corticosteroids in inducing a remission in patients with acute Crohn's disease. In conclusion, nutrition has both a supportive and therapeutic role in the management of chronic gastrointestinal diseases. With the development of modern techniques of nutritional support, the morbidity and mortality associated with chronic GI disease can be reduced. On the other hand, dietary manipulation may be used to treat to prevent specific GI disorders such as coeliac disease, functional bowel disease, Crohn's disease and colonic neoplasia. The future development of nutria-pharmaceuticals is particularly attractive in view of their low cost and wide safety margins.

Diet↗